Longevitytech.fund
VC Fund
Prague, Czech Republic
Longevitytech.fund is a VC fund in Prague focused on Biotechnology and Health Care. Longevitytech.fund do pre-seed and seed-stage investments in the best of worldwide early-stage startups and spinoffs based on our close cooperation with top scientists in the field of aging research and rejuvenation, biotechnology, bioinformatics, agetech, and related AI. We Provide an active approach with entrepreneurial help, network andcommercialization support. We also provide longevity program for our LPs.
- Total investments:
- 56
- Last investment:
- Lead investor:
- 32%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Longevitytech.fund invests in
Stages Longevitytech.fund invests in
Countries Longevitytech.fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $634k–$10M
- Pre-Seed
- $100k–$3.6M
Investment Focus
Industry
- Biotechnology 23 (41%)
- Health Care 19 (34%)
- Life Science 6 (11%)
- Personal Health 5 (9%)
- Biopharma 4 (7%)
Stage
- Seed 20 (36%)
- Convertible Note 14 (25%)
- Pre-Seed 10 (18%)
- Venture - Series Unknown 2 (4%)
- Angel 1 (2%)
Country
- United States 29 (52%)
- United Kingdom 7 (13%)
- The Netherlands 2 (4%)
- Greece 1 (2%)
- Israel 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Petr Sramek
Co-Founder, Chairman and Managing, General Partner
|
Co-Founder, Chairman and Managing, General Partner | Total investments: 4 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| DAGI: higher-level causal models from spatiotemporal coarse‑graining Whytics builds tools to reveal and validate macro‑causal structure—the stable, higher-level variables that appear when many parts of a system interact across space and time. | $100K / Pre-Seed / Jul 04, 2025 | ||
|
Klothea Bio
|
Klothea Bio is a protein well known for its powerful anti-aging capabilities, such as tumor suppression, neuroprotection, and antioxidative actions. As people age, their klotho levels drop to harmful levels. The metabolic disease syndrome will be the focus of the first investigations, while later studies will try to extend therapeutic applicationsto cancer, Alzheimer's disease, obesity, and other age-related diseases. | Seed / Nov 25, 2024 | |
| Using cutting edge mitochondrial science to develop cosmeceuticals and pharmaceuticals. | $7.5M / Seed / Feb 20, 2024 | ||
| MitoRx Therapeutics is a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction. | $5M / Seed / Dec 13, 2023 | ||
| Rejuvenation Technologies is a biotechnology company that developed nucleoside-modified TERT mRNA to safely and rapidly extend telomeres. The company is headquartered in Mountain View, California. | $10.6M / Seed / Sep 06, 2023 | ||
| SiPhox offers a handheld testing device with RNA/DNA and protein testing for point-of-care and At-Home solutions. The company's kit is made by multiplexing RNA, antibody, and antigen tests on a single silicon photonic chip which is amplified by plasmon resonance and silicon photonic resonator readout, enabling users to undertake tests fordisease safely and in a disposable point-of-care and at-home manner.SiPhox was founded in 2020 and is based in Cambridge, Massachusetts, USA. | $10M / Seed / Jul 19, 2023 | ||
| Cosmica Biosciences primarily engages in accelerating drug discovery for longevity. It utilizes unbiased multi-scale biology coupled with machine learning algorithms to develop precision-based interventions to extend the human lifespan on Earth and reduce health risks triggered by spaceflight exposures. Its platform leverages data generated fromhuman blood and organoids exposed to microgravity simulation and galactic radiation and spaceflight, as well as in vivo data from commercial and non-commercial crew members and onboard experiments from NASA, SpaceX, and Axiom | Pre-Seed / Jun 26, 2023 | ||
| Cleara is developing therapeutics to eliminate senescent cells. | $2.5M / Seed / Sep 22, 2022 | ||
| Remedium Bio is a Boston area gene therapy company focused on the development of curative treatments for a number of highly debilitating conditions. Our fundamental approach to product development utilizes proven technologies in novel ways to treat well-characterized disease pathology. To streamline R&D, we modularly apply elements of proventechnology to develop local, targeted treatments focusing on clinically validated molecules and mechanistic pathways. Today, our leading candidates include gene therapy treatments in the fields of Rheumatology / Osteoarthritis, Endocrinology / Diabetes, and Neurology / Stroke. | $2.3M / Seed / Aug 15, 2022 | ||
| Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. | $2.5M / Seed / Jun 09, 2022 | ||
| See all 56 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Longevitytech.fund invest in?
Longevitytech.fund invests primarily in Biotechnology, Health Care and Life Science startups, most often at Seed and Convertible Note stage. Most of the 56 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Longevitytech.fund's check size?
Longevitytech.fund typically joins rounds of $634k–$10M at Seed and $100k–$3.6M at Pre-Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Longevitytech.fund participates in.
How do I contact Longevitytech.fund?
Public channels for Longevitytech.fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Longevitytech.fund?
The team at Longevitytech.fund includes Petr Sramek (Co-Founder, Chairman and Managing, General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
